Pharmaceuticals
Italy Diabetes Drugs Market Analysis
The Italy diabetes drugs market size was valued at $1.48 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.6% from 2022 to 2030 and will reach $2.29 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Italy diabetes drug market will grow because, the Italian government has implemented a range of initiatives aimed at improving diabetes management and reducing the burden of the disease on the healthcare system. The key market players are Chiesi Farmaceutici (ITA), Menarini Group (ITA), Boehringer Ingelheim, Sanofi, Boehringer Ingelheim and others.
Buy Now
Italy Diabetes Drugs Market Executive Summary
The Italy diabetes drugs market size was valued at $1.48 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.6% from 2022 to 2030 and will reach $2.29 Bn in 2030. In Italy, healthcare is largely funded by the government through the National Health Service (Servizio Sanitario Nazionale or SSN). The SSN is funded by taxes, and provides universal healthcare coverage to all citizens and legal residents. Italy has a relatively high level of healthcare expenditure compared to other European countries. According to data from the Organization for Economic Cooperation and Development (OECD), healthcare expenditure in Italy was equivalent to 8.8% of GDP in 2019, which is above the OECD average of 8.4%.
The Italian government has been making efforts to control healthcare spending in recent years, as the cost of providing healthcare services continues to rise. This has included measures such as cost containment programs, which aim to reduce the cost of drugs and medical devices, and efforts to increase efficiency in the healthcare system.
Diabetes is a significant health concern in Italy, with an estimated 3.5 Mn people living with the condition. The prevalence of diabetes in Italy is increasing, driven by factors such as an aging population, sedentary lifestyles, and poor dietary habits. The impact of diabetes epidemic in Italy has had a significant impact on the diabetes drugs market. As more people are diagnosed with diabetes, there is an increasing demand for effective treatments that can help manage the condition and improve patient outcomes. This has created opportunities for pharmaceutical companies to develop and market new diabetes drugs in Italy. At the same time, the Italian government has been taking steps to improve the management of diabetes and reduce the burden of the disease on the healthcare system. This has included initiatives to promote healthy lifestyles, improve diabetes education and awareness, and increase access to diabetes drugs and services.
In recent years, the Italian government has also been implementing cost containment measures to control the rising cost of healthcare, including diabetes drugs. This has created challenges for pharmaceutical companies operating in the Italian market, as they face pressure to reduce drug prices and demonstrate the value of their products. The increasing prevalence of diabetes, coupled with the need for more effective treatments and government initiatives to improve diabetes management, create opportunities for companies to develop and market innovative new therapies for this growing patient population.
Market Dynamics
Market Growth Drivers Analysis
The prevalence of diabetes is increasing in Italy, which is driving demand for diabetes drugs. According to the International Diabetes Federation, an estimated 3.5 Mn people in Italy have diabetes. This represents a significant patient population that requires ongoing treatment and management, creating opportunities for pharmaceutical companies to develop and market new diabetes drugs.
Additionally, the Italian government has implemented a range of initiatives aimed at improving diabetes management and reducing the burden of the disease on the healthcare system. These initiatives include programs to promote healthy lifestyles, increase diabetes education and awareness, and improve access to diabetes drugs and services. These efforts are expected to drive demand for diabetes drugs in Italy, as more people are diagnosed with the condition and require effective treatments.
Furthermore, advances in technology are enabling the development of new and innovative diabetes treatments. For example, continuous glucose monitoring (CGM) systems and insulin pumps are becoming increasingly popular in Italy, providing patients with more effective and convenient ways to manage their condition. These advances are creating opportunities for pharmaceutical companies to develop new diabetes drugs that can work in conjunction with these technologies to provide more effective treatment options.
Market Restraints
The Italian government has been implementing cost containment measures to control the rising cost of healthcare, including diabetes drugs. This has created challenges for pharmaceutical companies operating in the Italian market, as they face pressure to reduce drug prices and demonstrate the value of their products. This could limit the profitability of the diabetes drugs market in Italy. Additionally, many diabetes drugs have gone off-patent in recent years, leading to the entry of generic drugs into the market. This has increased competition in the diabetes drugs market in Italy, and has put pressure on prices. Pharmaceutical companies must compete with lower-priced generic drugs, which could limit their profitability and growth potential in the market.
Moreover, the Italian Medicines Agency (AIFA) is responsible for regulating diabetes drugs in Italy, and requires rigorous testing and approval processes before drugs can be approved for use. This can be a time-consuming and costly process for pharmaceutical companies, and may limit the number of new diabetes drugs that are brought to market in Italy. Additionally, AIFA may require post-marketing surveillance and monitoring, which can add additional costs and complexity to the drug development process.
Competitive Landscape
Key Players
- Chiesi Farmaceutici (ITA)
- Menarini Group (ITA)
- Boehringer Ingelheim
- Sanofi
- Boehringer Ingelheim
- Eli Lilly and Company
- AstraZeneca
- Johnson & Johnson
- Bayer Pharmaceuticals
- Novo Nordisk
- Merck
- Novartis
- GlaxoSmithKline
Notable deals
May 2021: Novo Nordisk announced a collaboration with Italian biotech company Energesis Pharmaceuticals to develop a new class of diabetes treatments. The collaboration will focus on developing small molecule drugs that target GPRC6A, a receptor involved in glucose and bone metabolism.
June 2021: Sanofi announced a research collaboration with Italian biotech company Fimbrion Therapeutics to develop new treatments for uropathogenic Escherichia coli (UPEC) infections, which can be a complication of diabetes.
July 2021: Chiesi Farmaceutici entered into a licensing agreement with Zealand Pharma to commercialize glepaglutide, a GLP-2 agonist for the treatment of short bowel syndrome, in Italy and other European countries.
Healthcare Policies and Regulatory Landscape
Policy changes and Reimbursement scenario
The regulation of diabetes drugs in Italy is the responsibility of the Italian Medicines Agency (AIFA), which is a regulatory agency under the authority of the Ministry of Health. The AIFA is responsible for evaluating the safety, efficacy, and quality of drugs before they are approved for use in Italy. Before a diabetes drug can be approved in Italy, it must undergo a rigorous testing and approval process that includes preclinical and clinical trials. The drug manufacturer must provide extensive data on the safety and efficacy of the drug, including its potential side effects and interactions with other medications. Once a diabetes drug is approved for use in Italy, it is subject to ongoing monitoring and surveillance by the AIFA to ensure that it continues to meet safety and efficacy standards.
In Italy, diabetes drugs are typically reimbursed through the country's National Health Service (Servizio Sanitario Nazionale or SSN), which provides coverage to all citizens and legal residents. The reimbursement system is based on a formulary, which is a list of drugs that are approved for reimbursement by the SSN. To be included on the formulary, a diabetes drug must demonstrate a significant benefit over existing treatments, and its cost must be reasonable in relation to its benefit. The Italian Medicines Agency (AIFA) considers a range of factors when making reimbursement decisions, including the drug's clinical effectiveness, its cost, and its impact on patient outcomes.
Once a diabetes drug is approved for reimbursement, it is typically covered by the National Health Service. However, patients may still be responsible for a co-pay or deductible, depending on their specific insurance plan. Some diabetes drugs may also be covered by private health insurance plans, depending on the terms of the individual policy.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Diabetes Drugs Market Segmentation
By Drug Type (Revenue, USD Bn):
The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :
- Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
- Exenatide (Byetta)
- Dulaglutide (Trulicity)
- Semaglutide (Ozempic, Wegovy)
- Liraglutide (`Saxenda, Victoza)
- Lixisenatide (Adlyxin)
- Pramlintide (Symlin)
- Tirzepatide (Mounjaro)
- Albiglutide (Tanzeum)
- Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)
By Application (Revenue, USD Bn):
Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.
- Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
- Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
- Other diabetes types
By Distribution Channel (Revenue, USD Bn):
Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Insights10 will provide you with the reports within 10 key parameters which are:
- Market Overview
- Market Growth Drivers & Restraints
- Epidemiology of Disease Type
- Market Segmentation
- Market Share
- Competitive Landscape
- Key Company Profiles
- Healthcare Policies & Regulatory Framework
- Reimbursement Scenario
- Factors Driving Future Growth
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
(1).png)
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
- Establishing market drivers and trends
- Analyzing the regulatory landscape to understand future growth
- Market Segment based analysis to obtain revenue/volume
- Analyzing current needs and determining penetration to estimate the market
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
- Intelligent insights to take informed business decisions
- Qualitative, acute and result oriented market analysis
- Market size and forecasts from 2022 to 2030
- Opportunities for expansion and in-depth market analysis
- Segmentation and regional revenue forecasts
- Analysis of the market share and competitive landscape
- Strategic Recommendations to chart future course of action
- Comprehensive Market Research Report in PDF and PPT formats
Need more?
- Ask our analyst how this study was put together to learn more
- Discuss additional requirements as part of the free customisation
- Add more countries or regions to the scope
- Get answers to specific business questions
- Develop the business case to launch the product
- Find out how this report may influence your business revenue
Related reports (by category)
Pharmaceuticals
India Oncology Drugs Market Analysis
Pharmaceuticals
Germany Dry Eye Medication Market Analysis
Related reports (by geography)
Medical Devices